skip to the content

Clinical Trials

Acute Myeloid Leukemia - Allogeneic Transplant Study

CALGB 100103: A Phase II Study of Allogeneic Transplant for Older Patients with AML in First Morphologic complete remission using a Non-Myeloablative preparation regimen

Protocol ID

07-121

Protocol Description

The goal of this study is to replace the defective cells responsible for acute myeloid leukemia with normal cells from a non-affected donor. This experimental treatment is a new approach that attempts to stimulate a patient's own immune system to fight his/her disease.

Eligibility Criteria

Patients with acute myeloid leukemia and non-affected donors

Primary Investigator(s)

  • Ruthee-Lu Bayer, MD

Contact Information

Marisa Lemonides, RN
(516) 734-8218
mlemonid@nshs.edu

Last Update

March 26, 2010
top
  • Share this Page
  • Bookmark this Page
  • Toggle Text Size
  • Print this Page
Search Cancer:
top
top